Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

GlobeNewswire July 26, 2021

NovaBay Pharmaceuticals Partners with Harrow Health's ImprimisRx® to Promote Prescription Avenova

Business Wire July 19, 2021

Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation

GlobeNewswire July 15, 2021

Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026

GlobeNewswire June 17, 2021

Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026

GlobeNewswire June 14, 2021

Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and "BB" Rating from Egan-Jones

GlobeNewswire June 14, 2021

Visionology Acquires Exclusive Worldwide License to SPARCS Contrast Sensitivity Testing Technology

GlobeNewswire June 3, 2021

Harrow Health Launches New Corporate and Investor Website

GlobeNewswire June 1, 2021

Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx's Proprietary Klarity-C® Drops

GlobeNewswire May 17, 2021

Harrow Health Announces Record First Quarter 2021 Financial Results

GlobeNewswire May 11, 2021

Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock

GlobeNewswire May 5, 2021

Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes

GlobeNewswire May 5, 2021

Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021

GlobeNewswire April 27, 2021

Harrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026

GlobeNewswire April 20, 2021

Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026

GlobeNewswire April 15, 2021

Harrow Health Announces Offering of $25 Million Senior Notes Due 2026 and "BB" Rating from Egan-Jones

GlobeNewswire April 14, 2021

Harrow Health Announces Preliminary First Quarter 2021 Financial Results

GlobeNewswire April 14, 2021

Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results

GlobeNewswire March 8, 2021

Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021

GlobeNewswire February 25, 2021